Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Credit Suisse Reiterates Neutral on Wendy’s, Maintains $24 Price Target

Credit Suisse Reiterates Neutral on Wendy’s, Maintains $24 Price Target

Credit Suisse analyst Lauren Silberman reiterates Wendy's (NASDAQ:WEN) with a Neutral and maintains $24 price target.

byBenzinga Newsdesk

March 2, 2023

1 minute read

Credit Suisse analyst Lauren Silberman reiterates Wendy’s (NASDAQ:WEN) with a Neutral and maintains $24 price target.

Here’s How Much $100 Invested In Diamondback Energy 10 Years Ago Would Be Worth Today

By Benzinga Insights

August 30, 5:00 PM

Diamondback Energy (NASDAQ:FANG) has outperformed the market over the past 10 years by 3.15% on an annualized basis…

FANG

Danish Brewer Carlsberg’s CEO Reveals Retirement Plan

By Shivani Kumaresan

March 7, 7:28 AM

Carlsberg A/S (OTC:CABGY) Chief Executive Officer Cees ‘t Hart is set to retire after eight years in the role. He will…

CABGY

Builders FirstSource Sees FY23 Capital Expenditures $300M-$350M

By Benzinga Newsdesk

February 28, 8:09 AM

Q1 2023 Total Company Guidance The Company expects challenging conditions in housing amid elevated mortgage rates and general uncertainty in economic conditions that may significantly impact the business. As a

BLDR

Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC’s ‘Final Trades’

By Avi Kapoor

May 15, 9:07 AM

Pfizer is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform.

FCX

Credit Suisse Reiterates Neutral on Wendy’s, Maintains $24 Price Target

Related Posts

Here’s How Much $100 Invested In Diamondback Energy 10 Years Ago Would Be Worth Today

Danish Brewer Carlsberg’s CEO Reveals Retirement Plan

Builders FirstSource Sees FY23 Capital Expenditures $300M-$350M

Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC’s ‘Final Trades’